Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Receivables (2019 - 2025)

Catalyst Pharmaceuticals' Receivables history spans 7 years, with the latest figure at $126.5 million for Q4 2025.

  • For Q4 2025, Receivables rose 93.17% year-over-year to $126.5 million; the TTM value through Dec 2025 reached $126.5 million, up 93.17%, while the annual FY2025 figure was $126.5 million, 93.17% up from the prior year.
  • Receivables reached $126.5 million in Q4 2025 per CPRX's latest filing, up from $106.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $126.5 million in Q4 2025 to a low of $5.6 million in Q1 2021.
  • Average Receivables over 5 years is $42.7 million, with a median of $45.4 million recorded in 2023.
  • Peak YoY movement for Receivables: decreased 19.04% in 2021, then skyrocketed 414.61% in 2023.
  • A 5-year view of Receivables shows it stood at $6.6 million in 2021, then skyrocketed by 57.71% to $10.4 million in 2022, then skyrocketed by 412.64% to $53.5 million in 2023, then rose by 22.35% to $65.5 million in 2024, then surged by 93.17% to $126.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Receivables are $126.5 million (Q4 2025), $106.4 million (Q3 2025), and $65.9 million (Q2 2025).